期刊文献+

辛伐他汀对2型糖尿病患者血管内皮功能及炎症因子的影响 被引量:8

The effects of simvastatin therapy on endothelial function and inflammatory factor in type 2 diabetes mellitus without cardiovascular disease
下载PDF
导出
摘要 目的观察辛伐他汀对2型糖尿病患者血管内皮功能及炎症因子的影响。方法选择30例2型糖尿病(T2DM)患者及25例对照者,给予辛伐他汀20mg/d治疗12个月。分别于治疗前、治疗1个月及12个月时,检测肱动脉血流介导性扩张,并测定主要血脂参数、超敏C反应蛋白(hsCRP)、空腹血糖(FPG)、胰岛素(FIns)和胰岛素抵抗指数(HOMA-IR)。结果①辛伐他汀治疗可明显改善T2DM组及对照组患者血脂水平。②辛伐他汀治疗1个月后,T2DM组患者肱动脉内皮依赖性舒张功能(FMD)较治疗前无明显变化[(5.94±0.87)%vs.(5.65±0.65)%,P﹥0.05],治疗12个月后,FMD虽有上升趋势[(6.10±0.71)%],但仍无显著性差异。辛伐他汀可明显改善对照组的FMD。③治疗12个月时T2DM组患者血清hs-CRP水平由(15.21±3.71)mg/L降至(10.51±2.90)mg/L(P﹤0.01)。④辛伐他汀对T2DM患者FPG、FIns及HOMA-IR均无影响。结论辛伐他汀治疗12个月,尽管可以显著降低T2DM患者血脂水平,减轻炎症反应,但受损的血管内皮功能并未得到改善。 Objective To investigate the effects of simvastatin on vascular endothelial function and hypersensitivity C-reactive protein (hs-CRP) in patients with type 2 diabetes mellitus (T2DM). Methods A total of 32 T2DM patients and 25 control subjects received the treatment of 20 mg/d simvastatin for 12 months. Endothelial dependent flow-mediated vasodilation (FMD) was assessed at baseline, after 1 month and 12 months of simvastatin therapy. Serum lipid profiles, hs-CRP, fasting glucose (FPG), fasting insulin (Fins) and homeostasis model assessment-insulin resistance (HOMA-IR) were measured simultaneously. Results①Simvastatin significantly improved serum lipid disorders in patients with T2DM.②Compared with baseline level, there was no change of FMD in pateints with T2DM after one month simvastatin treatment. Furthermore, no significant increase of FMD was found after 12-month simvastatin treatment [(5.65±0.65)% vs. (6.10±0.71)%, P 〉 0.05]. In contrast, simvastatin treatment caused a significant improvement of FMD in control subjects.③A significant reduction of hs-CRP level was observed in patients with T2DM after 12-month treatment.④Simvastatin had no effect on FPG, Fins and HOMA-IR in both groups. Conclusions Despite of substantial lowering of lipid parameters and inflammatory marker after 12-month simvastatin therapy, no improvement of endothelium-dependdnt vasodilation is found in T2DM.
出处 《北京医学》 CAS 2010年第1期1-3,共3页 Beijing Medical Journal
基金 国家自然科学基金(30240036)
关键词 辛伐他汀 2型糖尿病 内皮功能 超敏C反应蛋白 Simvatatin Type 2 diabetes mellitus Endothelial function Hypersensitive C-reactive protein
  • 相关文献

参考文献7

  • 1Chen H, Ren JY, Xing Y, et al. Short-term withdrawal of simvastatin induces endothelial dysfunction in patients with coronary artery disease: a dose-response effect dependent on endothelial nitric oxide synthase. Int J Cardiol, 2009, 131 : 313-320.
  • 2Akalin A, Temiz G, Akcar N, et al. Short term effects of atorvastatin on endothelial functions and oxidized LDL levels in patients with type 2 diabetes. Endocr J, 2008, 55: 861-866.
  • 3Van Venrooij FV, van de Ree MA, Bots ML, et al. DALI Study Group. Aggressive lipid lowering does not improve endothelial function in type 2 diabetes: the Diabetes Atorvastatin Lipid Intervention (DALI) Study: a randomized, double-blind, placebo-controlled trial. Diabetes Care, 2002, 25:1211 - 1216.
  • 4Corretti MC, Anderson TJ, Benjamin EJ, et al. Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery: a report of the International Brachial Artery Reactivity Task Force. J Am Coll Cardiol, 2002, 39 : 257-265.
  • 5Rask-Madsen C, King GL. Mechanisms of disease: endothelial dysfunction in insulin resistance and diabetes. Nat Clin Pract Endocrinol Metab, 2007, 3:46-56.
  • 6崔红,韩燕,梁国红,吴勇伟.辛伐他汀对冠心病患者高敏C-反应蛋白的影响[J].北京医学,2008,30(10):635-635. 被引量:1
  • 7李建华,张惠芳,刘敏,陈征.早期辛伐他汀治疗对急性脑梗死患者血脂和炎症反应标志物C-反应蛋白浓度的影响[J].北京医学,2006,28(6):354-356. 被引量:9

二级参考文献16

  • 1Torzewski J,Torzewski M,Bowyer DE,et al.CRP frequency colocalizes with terminal complement complex in the intina of early atherosclerotic lesion of human coronary arteries.Areterioscler Thromb Vasc Biol,1998,18:1386.
  • 2Riesen WF,Engler H,Risch M,et al.Short-term effects of atorvastatin on C-reactive protein.Eur Heart J,2002,23:794-799.
  • 3Maseri A.Inflammation,atherosclerosis,and ischemic events-exploring the hidden side of the moon.Engl J Med,1997,336:1014-1016.
  • 4Ridlker PM,Cushman M,Stampfer M J,et al.Inflammation,aspirin,and the risk of cardiovascular disease in apparently healthy men.N Engl J Med,1997,336:973-979.
  • 5Lagrand WK,Visser CA,Hermens WT,et al.C-reactive protein as a cardiovascular risk factor more than an epiphenomenona.Circulation,1999,100:96.
  • 6Bickel C,Rupprecht HJ,Blankenberg S,et al.Relation of markers of infammation (C-reactive protein,fibrinogen,von Willebrand factor,and leukocyte count) and statin therapy to long-term mortality in patient with angiographically proven coronary artery disease.Am J Cardiol,2002,89:901-908.
  • 7Ridker PM,Rifai N,Marc A,et al.Inflammation,pravas-tatin,and the rish of coronary events after myocardial infarction in patients with average cholesterol levels.Circulation,1998,98:839-844.
  • 8Sachs FM,Pfeffer MA,Move LA,et al.The effect of pravastatin on coronary events after myocardial infarction inpatients with average cholestero llevels.N Engl J Med,1996,335:1001-1009.
  • 9Muirwei CJ,Alwan W.C-reactive protein and outcome after scheme stroke.Lancet,1999,30:981.
  • 10Scandinaavian Simvastatin Survial Study Group. Randomized trial of cholesterol-lowering in 4444 patients with coronary heart disease. Lancet, 1994, 344:1383 - 1389.

共引文献8

同被引文献92

引证文献8

二级引证文献40

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部